Medicine
Symtuza 150 mg/800 mg/200 mg/10 mg tablet
Symtuza 150 mg/800 mg/200 mg/10 mg tablet is a prescription medicine containing Cobicistat, Darunavir, Emtricitabine and Tenofovir alafenamide for oral use, marketed by Janssen Products, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C–25°C (between 68°F–77°F), with excursions permitted to 15°C–30°C…
Key facts
- Active ingredient (INN)
- Cobicistat, Darunavir, Emtricitabine and Tenofovir alafenamide
- Brand
- Symtuza
- Strength
- 150 mg/800 mg/200 mg/10 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Janssen Products
- Manufacturer
- Janssen Products
- Origin register
- US FDA, United States
- Storage
- Store at 20°C–25°C (between 68°F–77°F), with excursions permitted to 15°C–30°C (59°F–86°F). Keep container tightly closed with desiccant inside to protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AR22 Cobicistat, Darunavir, Emtricitabine and Tenofovir alafenamide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 July 2018
- Identifiers
- RxCUI 2049671, 2049677DailyMed set ID 85a17d00-6b7c-41ea-a6b3-5ad924820dabNDC 59676-800Application NDA210455
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 59676-800-30 | Janssen Products | 17 July 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Cobicistat, Darunavir, Emtricitabine and Tenofovir alafenamide is a fixed-dose combination of a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor, a cytochrome P450 3A inhibitor and a hepatitis B virus nucleoside analog reverse transcriptase inhibitor. MedsAcross supplies Cobicistat, Darunavir, Emtricitabine and Tenofovir alafenamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Cobicistat, Darunavir, Emtricitabine and Tenofovir alafenamideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Symtuza prescribing information (Janssen Products) · U.S. National Library of Medicine, DailyMed
- Symtuza: European public assessment report (EPAR) · European Medicines Agency
Need Symtuza 150 mg/800 mg/200 mg/10 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.